Related Experiment Video
Updated: Feb 2, 2026

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
α4β7 integrin inhibitors: a patent review
Hao Li1, Shi-Ying Huang1, Fang-Hong Shi2
1a Department of Pharmacy , Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine , Shanghai , China.
Alpha4beta7 integrin inhibitors show promise for treating various inflammatory diseases. Approved monoclonal antibodies like Natalizumab and Vedolizumab, alongside emerging small molecules and peptides, offer new therapeutic avenues.
Area of Science:
- Immunology
- Pharmacology
- Gastroenterology
Background:
- Alpha4beta7 integrin is a leukocyte cell surface receptor.
- Mucosal Addressing Cell Adhesion Molecule 1 (MAdCAM-1) is its exclusive ligand.
- This interaction is crucial in inflammatory processes.
Purpose of the Study:
- To review the discovery and development of alpha4beta7 integrin inhibitors.
- To explore their therapeutic applications in various immune-mediated diseases.
- To provide expert opinion on current and future treatments.
Main Methods:
- Review of scientific literature on alpha4beta7 integrin inhibitors.
- Analysis of clinical trial data for approved and investigational drugs.
- Synthesis of expert opinion on therapeutic potential.
Main Results:
- Monoclonal antibodies Natalizumab and Vedolizumab are clinically approved.
- Etrolizumab and AMG-181 are promising investigational antibodies targeting alpha4beta7.
- Small molecules (e.g., AJM300, CDP323) and peptide inhibitors show therapeutic potential.
Conclusions:
- Alpha4beta7 integrin inhibitors represent a significant therapeutic class.
- Diverse drug modalities are under investigation for inflammatory conditions.
- Targeting alpha4beta7 offers a promising strategy for immune-mediated diseases.
Related Concept Videos
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Dipeptidyl Peptidase 4 Inhibitors

